Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord

Gene Therapy

Volumn 9, Issue 20, 2002, Pages 1387-1395

  Eaton, M J ^a,b   Blits, B ^a,c   Ruitenberg, M J ^c   Verhaagen, J ^c   Oudega, M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain derived neurotrophic factor; CCI; Nerve injury; Persistent pain; Virus mediated gene transfer

Indexed keywords

ADENOVIRUS VECTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; SODIUM CHLORIDE;

ADENO ASSOCIATED VIRUS; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DORSAL ROOT; FEMALE; GENE OVEREXPRESSION; GENE TRANSFER; HINDLIMB; HUMAN; HYPERALGESIA; IN SITU HYBRIDIZATION; LUMBAR SPINAL CORD; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN; SPINAL CORD INJURY; THORACIC SPINE; VENTRAL ROOT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPENDOVIRUS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PAIN, INTRACTABLE; RATS; RATS, INBRED WF; SCIATIC NERVE; SPINAL CORD;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA;

EID: 0036772908     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301814     Document Type: Article

References (76)

1. Dickenson AH, Chapman V, Green GM. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharm 1997; 28: 633-638.
2. Kerchner GA, Li P, Zhuo M. Speaking out of turn: a role for silent synapses in pain. IUBMB Life 1999; 48: 251-256.
3. Kawamata M, Omote K. Involvement of increased excitatory amino acids and intracellular Ca2+ concentration in the spinal dorsal horn in an animal model of neuropathic pain. Pain 1996; 68: 85-96.
4. Zhang A-L, Hao J-X, Seiger A, Xu X-J. Decreased GABA immunoreactivity in spinal cord dorsal horn neurons after transient spinal cord ischemia in the rat. Brain Res 1994; 656: 187-190.
5. Kingery WS, Fields RD, Kocsis JD. Diminished dorsal root GABA sensitivity following chronic peripheral nerve injury. Exp Neurol 1988; 100: 478-490.
6. Deng YS, Zhong JH, Zhou XF. Effects of endogenous neurotrophins on sympathetic sprouting in the dorsal root ganglia and allodynia following spinal nerve injury. Exp Neurol 2000; 164: 344-350.
7. Zhou XF, Deng YS, Man CJ, Zhong JH. Neurotrophins from dorsal root ganglia trigger allodynia after spinal nerve injury in rats. Eur J Neurosci 2001; 12: 100-105.
8. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164.
9. Ohsawa F, Widmer HR, Knusel B, Denton TL. Response of embryonic rat hippocampal neurons in culture to neurotropin-3, brain-derived neurotrophic factor and basic fibroblast factor. Neurosci 1993; 57: 67-77.
10. Hyman C, Juhasz M, Jackson C, Wright P. Overlapping and distinct actions of the neurotrophins BDNF, NT-3 and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 1994; 14: 335-347.
11. Martin-Iverson MT, Todd KG, Altar CA. Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine. J Neurosci 1994; 14: 1262-1270.
12. Zhou X, Rush R. Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. Neurosci 1996; 74: 945-953.
13. Cho H, Kim J, Park H, Kim D. Changes in brain-derived neurotrophic factor immunoreactivity in rat dorsal root ganglia, spinal cord, and gracile nuclei following cut or crush injuries. Exp Neurol 1998; 154: 224-230.
14. Hermens WT, Verhaagen J. Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol 1998; 55: 399-432.
15. Kaplitt M, Makimura H. Defective viral vectors as agents for gene transfer in the nervous system. J Neurosci Meth 1997; 71: 125-132.
16. Bankiewicz K, Leff S, Nagy D, Jungles S. Practical aspects of the development of ex vivo and in vivo gene therapy for parkinson's disease. Exp Neurol 1997, 144: 147-156.
17. Rolling F, Samulski R. AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol Biotech 1995; 3: 9-15.
18. Peel MJ, Zolotukhin S, Schrimsher GW, Muzyczka N. Efficient transduction of green fluorescence protein in spinal cord neurons using adeno-associated virus vectors containing cell type specific promoters. Gene Therapy 1997; 4: 16-24.
19. Kaplitt M, Leone P, Samulski R, Xiao X. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Gen 1994; 8: 148-154.
20. McCown T, Xiao X, Li J, Breese G. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
21. Holtmaat A, Hermens W, Sonnemans M, Giger R. Adenoviral vector-mediated expression of B-50/GAP-43 induces alterations in the membrane organization of olfactory axon terminals in vivo. J Neurosci 1997; 17: 6575-6586.
22. Bueler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem 1999; 380: 613-622.
23. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Meth 2000; 98: 95-104.
24. Klein RL, Meyer EM, Peel AL, Zolotukhin S. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150: 183-194.
25. Klein RL, Lewis MH, Muzyczka N, Meyer EM. Prevention of 6-hydroxydopamine-indiced rotational behavior by BDNF somatic gene transfer. Brain Res 1999; 847: 314-320.
26. Loeb JE, Cordier WS, Harris ME, Weitzman MD. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295-2305.
27. Paterna JC, Moccetti T, Mura A, Feldon J. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Therapy 2000; 7: 1304-1311.
28. Oudega M et al. Amelioration of chronic neuropathic pain by adeno-associated viral (AAV) vector-mediated overexpression of BDNF in the rat spinal cord. Soc Neurosci Abstr 2000; 26: 169a.
29. Arenas E, Akerud P, Wong V, Boylan C. Effects of BDNF and NT4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo. Eur J Neurosci 1996; 8: 1707-1717.
30. Larkfors L, Lindsay RM, Alderson RF. Characterization of the responses of Purkinje cells to neurotrophin treatment. J Neurochem 1996; 66: 1362-1373.
31. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243-256.
32. Spenger C, Hyman C, Studer L, Egli M. Effects of BDNF on dopaminergic, serotonergic and GABA ergic neurons in cultures of human fetal ventral mesencephalon. Exp Neurol 1995; 133: 50-63.
33. Siuciak JA, Altar CA, Wiegand SJ, Lindsay RM. Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3. Brain Res 1994; 63: 326-330.
34. Xu XM, Guenard V, Kleitman N, Bunge MB. A combination of BDNF and NT-3 promotes supraspinal axonal regeneration into Schwann cell grafts in adult rat thoracic spinal cord. Dev Biol 1995; 168: 124-137.
35. Eaton MJ, Plunkett JA, Martinez MA, Karmally S. Changes in GAD and GABA imummoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic neurons. J Chem Neuroanat 1998; 16: 57-72.
36. Olson L. Grafts and growth factors in CNS. Basic science with clinical promise. Stereo Func Neurosurg 1990; 54: 250-267.
37. Hao J-X, Xu X-J, Aldskogius H, Seiger A. Chronic pain related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain 1992; 48: 279-290.
38. Yaksh TL. Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonists. Pain 1989; 37; 111-123.
39. Stiller CO, Cui JG, O'Connor WT, Brodin EG. ABA-ergic mechanisms may be involved in the spinal cord stimulation induced reversion of allodynia: animal studies with microdialysis. Am Pain Soc Abs 1995; 95: 801.
40. Kjaer M, Nielsen H. The analgesic effect of the GABA-agonist THIP in patients with chronic pain of malignant origin. Br J Clin Pharm 1983; 16: 477-485.
41. Klein R. Role of mouse neurotrophins in mouse neuronal development. FASEB J 1994, 8: 738-744.
42. Koliatsos VE, Clatterbuck RE, Winslow JW, Cayouette MH. Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo. Neuron 1993; 10: 359-367.
43. McMahon SB, Armanini MP, Ling L, Phillips HS. Expression and coexpression of trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets. Neuron 1994; 12: 1161-1171.
44. Schectersom. L, Bothwell M. Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons. Neuron 1992; 9: 449-463.
45. Michael G, Averill S, Nitkunan A, Rattray M. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 1997, 17: 8476-9490.
46. Griesbeck O, Canossa M, Campana G, Gartner A. Are there differences between secretion characteristics of NGF and BDNF? Implications for the modulatory role of neurotrophins in activity-dependent neuronal plasticity. Microsc Res Tech 1999; 45: 262-275.
47. Thompson S, Bennett D, Kerr B, Bradbury E. Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Nat Acad Sci USA 1999; 96:7714-7718.
48. Kerr B, Bradbury E, Bennet D, Trivedi P. Brain-derived neurotropic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999; 19: 5138-5148.
49. Rutherford LC, Nelson S, Turrigiano G. BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses. Neuron 1998; 21: 521-530.
50. Oyelese A, Rizzo M, Waxman S, Kocsis J. Differential effects of NGF and BDNF on axotomy-induced changes in GABA (A)-receptor-mediated conductance and sodium currents in cutaneous afferent neurons. J Neurophysiology 1997; 78: 31-42.
51. Frank L, Wiegand SJ, Siuciak JA, Lindsay RM. Effects of BDNF infusion on the regulation of TrkB protein and message in adult rat brain. Exp Neurol 1997; 145: 62-70.
52. Eaton MJ, Staley JK, Globus MYT, Whittemore SR. Developmental regulation of early serotonergic neuronal differentiation: The role of brain-derived neurotrophic factor and membrane depolarization. Dev Biol 1995; 170: 169-182.
53. Eaton MJ, Dancausse HR, Santiago DI, Whittemore SR. Lumbar transplants of immortalized serotonergic neurons alleviates chronic neuropathic pain. Pain 1997; 72: 59-69.
54. Hains BC, Johnson KM, McAdoo DJ, Eaton MJ. Engraftment of immortalized serotonergic neurons enhances locomotor function and attenuates pain-like behavior following spinal hemisection injury in the rat. Exp Neurol 2001; 171: 361-378.
55. Hains BC, Fullwood SD, Eaton MJ, Hulsebosch CE. Subdural engraftment of serotonergic neurons following spinal hemisection restores spinal serotonin, downregulates the serotonin transporter, and increases BDNF tissue content in the rat. Brain Res 2001; 913: 35-46.
56. Yaksh TL, Wilson PR. Spinal serotonin terminal system mediates antinociception. J Pharm Exp Ther 1979; 208: 446-453.
57. Davies JE. Roberts MHT. 5-hydroxytryptamine reduces substance P responses on dorsal interneurones: a possible interaction of neurotransmitters. Brain Res 1981; 217: 399-404.
58. Anden NE, Jukes MGM, Lundberg A. Spinal reflexes and monoamine liberation. Nature 1964; 202: 1222-1223.
59. Besson J-M. Serotonin and Pain. Excerpta Medica: New York, 1990.
60. Millan MJ. Serotonin and pain: evidence that activation of 5-HT1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in mice. Pain 1994; 58: 43-61.
61. Carter JE, Schuchman EH. Gene therapy for neurodegenerative diseases: fact or fiction? Br J Psychiatry 2001; 178: 392-394.
62. Crameri A, Whitehorn EA, Tate E, Stemmer WP. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol 1996; 14: 315-319.
63. Zolotukhin S, Potter M, Hauswirth WW, Guy J. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
64. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092.
65. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adeno associated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
66. Hermens WT, ter Brake O, Dijkhuizen PA, Sonnemans MA. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 1999; 10: 1885-1891.
67. Salvetti A, Oreve S, Chadeuf G, Favre D. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9: 695-706.
68. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107.
69. Cejas PJ, Martinez M, Karmally S, McKillop M. Lumbar transplant of neurons genetically modified to secrete brain-derived neurotrophic factor attenuate allodynia and hyperalgesia after sciatic nerve constriction. Pain 2000; 86: 195-210.
70. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-110.
71. Schaeren-Wiemers N, Gerfin-Moser A. A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labeled cRNA probes. Histochem 1993; 100: 431-440.
72. Giger RJ, Wolfer DP, De Wit GM, Verhaagen J. Anatomy of rat semaphorin III/collapsin-1 mRNA expression and relationship to developing nerve tracts during neuroembryogenesis. J Comp Nerol 1996; 375: 378-392.
73. Pasterkamp RJ, Giger RJ, Ruitenberg MJ, Holtmaat A. Expression of the gene encoding the chemorepellent semaphorin III is induced in the fibroblast component of neural scar tissue formed following injuries of adult but not neonatal CNS. Mol Cell Neurosci 1999; 13: 143-166.
74. Hargreaves K, Dubner R, Brown F, Flores C. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32: 77-88.
75. Chaplan SR, Bach FW, Pogrel JW, Chung JM. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Meth 1994; 53: 55-63.
76. Randall L, Selitto J. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn 1957, 4: 409-419.